S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

$1.24
-0.08 (-6.06%)
(As of 04/19/2024 ET)

Nektar Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$3.50
182.26% Upside
High Forecast$6.00
Average Forecast$3.50
Low Forecast$1.00
TypeCurrent Forecast
4/20/23 to 4/19/24
1 Month Ago
3/21/23 to 3/20/24
3 Months Ago
1/20/23 to 1/20/24
1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Hold
Hold
Reduce
Sell
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$3.50$3.50$3.00$2.50
Predicted Upside182.26% Upside264.66% Upside129.53% Upside34.57% Upside
Get Nektar Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

NKTR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NKTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nektar Therapeutics Stock vs. The Competition

TypeNektar TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside182.26% Upside985.03% Upside11.92% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/6/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$0.50 ➝ $1.00+11.16%
3/5/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderweight
11/9/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
8/7/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$6.00+488.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:25 PM ET.

NKTR Price Target - Frequently Asked Questions

What is Nektar Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Nektar Therapeutics stock is Hold based on the current 1 sell rating, 3 hold ratings and 1 buy rating for NKTR. The average twelve-month price prediction for Nektar Therapeutics is $3.50 with a high price target of $6.00 and a low price target of $1.00. Learn more on NKTR's analyst rating history.

Do Wall Street analysts like Nektar Therapeutics more than its competitors?

Analysts like Nektar Therapeutics less than other Medical companies. The consensus rating for Nektar Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how NKTR compares to other companies.

Does Nektar Therapeutics's stock price have much upside?

According to analysts, Nektar Therapeutics's stock has a predicted upside of 264.66% based on their 12-month stock forecasts.

What analysts cover Nektar Therapeutics?

Nektar Therapeutics has been rated by Jefferies Financial Group, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:NKTR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners